These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30776650)

  • 1. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
    Blokland A; Van Duinen MA; Sambeth A; Heckman PRA; Tsai M; Lahu G; Uz T; Prickaerts J
    Neurobiol Aging; 2019 May; 77():37-43. PubMed ID: 30776650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults.
    Van Duinen MA; Sambeth A; Heckman PRA; Smit S; Tsai M; Lahu G; Uz T; Blokland A; Prickaerts J
    Neuropharmacology; 2018 Mar; 131():31-38. PubMed ID: 29241652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
    Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.
    Heckman PRA; Van Duinen MA; Blokland A; Uz T; Prickaerts J; Sambeth A
    Psychopharmacology (Berl); 2018 Jan; 235(1):301-308. PubMed ID: 29098341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
    Gilleen J; Farah Y; Davison C; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Reichenberg A; Williams SC; Mehta MA; Shergill SS
    Psychopharmacology (Berl); 2021 May; 238(5):1279-1289. PubMed ID: 30536081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
    Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT
    Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
    Gilleen J; Nottage J; Yakub F; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Williams SC; Ffytche D; Mehta MA; Shergill SS
    J Psychopharmacol; 2021 Jan; 35(1):15-22. PubMed ID: 32854568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.
    Livingston NR; Hawkins PC; Gilleen J; Ye R; Valdearenas L; Shergill SS; Mehta MA
    J Psychopharmacol; 2021 Sep; 35(9):1099-1110. PubMed ID: 33908296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
    Kelly K; Mejia A; Suhasini AN; Lin AP; Kuhn J; Karnad AB; Weitman S; Aguiar RC
    Clin Cancer Res; 2017 Mar; 23(5):1186-1192. PubMed ID: 27542768
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
    Singh D; Lea S; Mathioudakis AG
    Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial.
    Possemis N; Verhey F; Prickaerts J; Blokland A; Ramakers I
    Trials; 2024 Mar; 25(1):162. PubMed ID: 38438923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
    Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
    J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
    Laube BL; Carson KA; Sharpless G; Paulin LM; Hansel NN
    J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):189-199. PubMed ID: 30964381
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
    Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
    J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
    Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B
    Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflumilast attenuates cognitive deficits in estrogen insufficient rats.
    Goyal A; Garabadu D
    Behav Pharmacol; 2020 Oct; 31(7):671-687. PubMed ID: 32516271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
    Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
    N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
    Park TS; Kang J; Lee JS; Oh YM; Lee SD; Lee SW
    Int J Chron Obstruct Pulmon Dis; 2019; 14():871-879. PubMed ID: 31354255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.